These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38723748)

  • 1. Prognostic significance of low hepatic fat content in advanced chronic liver disease: MRI-PDFF insights.
    Nakamura A; Yoshimura T; Ichikawa T; Okuyama K
    Ann Hepatol; 2024; 29(4):101507. PubMed ID: 38723748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe hepatic steatosis promotes increased liver stiffness in the early stages of metabolic dysfunction-associated steatotic liver disease.
    Kumada T; Toyoda H; Ogawa S; Gotoh T; Suzuki Y; Sugimoto K; Yoshida Y; Kuroda H; Kamada Y; Sumida Y; Ito T; Akita T; Tanaka J
    Liver Int; 2024 Jul; 44(7):1700-1714. PubMed ID: 38558221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the efficacy of 8 non-invasive models in predicting MASLD and progression: a prospective study.
    Yang A; Zhu X; Zhang L; Zhang D; Jin M; Lv G; Ding Y
    BMC Gastroenterol; 2024 Oct; 24(1):365. PubMed ID: 39402469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of hepatic fat loss in chronic liver disease: a study using MRI proton density fat fractionation.
    Nakamura A; Yoshimura T; Asakura H
    Eur J Clin Nutr; 2023 Feb; 77(2):264-269. PubMed ID: 36127391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective, Same-Day, Direct Comparison of Controlled Attenuation Parameter With the M vs the XL Probe in Patients With Nonalcoholic Fatty Liver Disease, Using Magnetic Resonance Imaging-Proton Density Fat Fraction as the Standard.
    Caussy C; Brissot J; Singh S; Bassirian S; Hernandez C; Bettencourt R; Rizo E; Richards L; Sirlin CB; Loomba R
    Clin Gastroenterol Hepatol; 2020 Jul; 18(8):1842-1850.e6. PubMed ID: 31843596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver stiffness measurement by magnetic resonance elastography is not affected by hepatic steatosis.
    Chen J; Allen AM; Therneau TM; Chen J; Li J; Hoodeshenas S; Chen J; Lu X; Zhu Z; Venkatesh SK; Song B; Ehman RL; Yin M
    Eur Radiol; 2022 Feb; 32(2):950-958. PubMed ID: 34432123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.
    Jayakumar S; Middleton MS; Lawitz EJ; Mantry PS; Caldwell SH; Arnold H; Mae Diehl A; Ghalib R; Elkhashab M; Abdelmalek MF; Kowdley KV; Stephen Djedjos C; Xu R; Han L; Mani Subramanian G; Myers RP; Goodman ZD; Afdhal NH; Charlton MR; Sirlin CB; Loomba R
    J Hepatol; 2019 Jan; 70(1):133-141. PubMed ID: 30291868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis.
    Wildman-Tobriner B; Middleton MM; Moylan CA; Rossi S; Flores O; Chang ZA; Abdelmalek MF; Sirlin CB; Bashir MR
    Gastroenterology; 2018 Nov; 155(5):1428-1435.e2. PubMed ID: 30031769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease.
    Idilman IS; Keskin O; Celik A; Savas B; Elhan AH; Idilman R; Karcaaltincaba M
    Acta Radiol; 2016 Mar; 57(3):271-8. PubMed ID: 25855666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-wide Studies Reveal Genetic Risk Factors for Hepatic Fat Content.
    Li Y; van den Berg EH; Kurilshikov A; Zhernakova DV; Gacesa R; Hu S; Lopera-Maya EA; Zhernakova A; ; de Meijer VE; Sanna S; Dullaart RPF; Blokzijl H; Festen EAM; Fu J; Weersma RK
    Genomics Proteomics Bioinformatics; 2024 Jul; 22(2):. PubMed ID: 39142818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of a motion-robust 2D sequential technique for quantification of hepatic proton density fat fraction during free breathing.
    Pooler BD; Hernando D; Ruby JA; Ishii H; Shimakawa A; Reeder SB
    J Magn Reson Imaging; 2018 Dec; 48(6):1578-1585. PubMed ID: 29665193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deep Learning for Inference of Hepatic Proton Density Fat Fraction From T1-Weighted In-Phase and Opposed-Phase MRI: Retrospective Analysis of Population-Based Trial Data.
    Wang K; Cunha GM; Hasenstab K; Henderson WC; Middleton MS; Cole SA; Umans JG; Ali T; Hsiao A; Sirlin CB
    AJR Am J Roentgenol; 2023 Nov; 221(5):620-631. PubMed ID: 37466189
    [No Abstract]   [Full Text] [Related]  

  • 13. Quantifying steatosis in the liver and pancreas with MRI in patient with chronic liver disease.
    Vieira J; Amorim J; Martí-Bonmatí L; Alberich-Bayarri Á; França M
    Radiologia (Engl Ed); 2020; 62(3):222-228. PubMed ID: 31932016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterisation of liver fat in the UK Biobank cohort.
    Wilman HR; Kelly M; Garratt S; Matthews PM; Milanesi M; Herlihy A; Gyngell M; Neubauer S; Bell JD; Banerjee R; Thomas EL
    PLoS One; 2017; 12(2):e0172921. PubMed ID: 28241076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial).
    Ajmera VH; Cachay E; Ramers C; Vodkin I; Bassirian S; Singh S; Mangla N; Bettencourt R; Aldous JL; Park D; Lee D; Blanchard J; Mamidipalli A; Boehringer A; Aslam S; Leinhard OD; Richards L; Sirlin C; Loomba R
    Hepatology; 2019 Nov; 70(5):1531-1545. PubMed ID: 31013363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.
    Cui J; Philo L; Nguyen P; Hofflich H; Hernandez C; Bettencourt R; Richards L; Salotti J; Bhatt A; Hooker J; Haufe W; Hooker C; Brenner DA; Sirlin CB; Loomba R
    J Hepatol; 2016 Aug; 65(2):369-76. PubMed ID: 27151177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone marrow fat content is correlated with hepatic fat content in paediatric non-alcoholic fatty liver disease.
    Yu NY; Wolfson T; Middleton MS; Hamilton G; Gamst A; Angeles JE; Schwimmer JB; Sirlin CB
    Clin Radiol; 2017 May; 72(5):425.e9-425.e14. PubMed ID: 28063601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of a high-SNR chemical-shift-encoded MRI with complex reconstruction for proton density fat fraction (PDFF) estimation overall and in the low-fat range.
    Park CC; Hooker C; Hooker JC; Bass E; Haufe W; Schlein A; Covarrubias Y; Heba E; Bydder M; Wolfson T; Gamst A; Loomba R; Schwimmer J; Hernando D; Reeder SB; Middleton M; Sirlin CB; Hamilton G
    J Magn Reson Imaging; 2019 Jan; 49(1):229-238. PubMed ID: 29707848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD.
    Permutt Z; Le TA; Peterson MR; Seki E; Brenner DA; Sirlin C; Loomba R
    Aliment Pharmacol Ther; 2012 Jul; 36(1):22-9. PubMed ID: 22554256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of Controlled Attenuation Parameter in Detecting and Monitoring Hepatic Steatosis with MRI-PDFF as Reference.
    Wang JH; Ou HY; Yen YH; Chen CH; Lu SN
    Dig Dis Sci; 2020 May; 65(5):1512-1519. PubMed ID: 31617130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.